<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pipeline Challenges on FinanClub</title>
    <link>https://finan.club/tags/pipeline-challenges/</link>
    <description>Recent content in Pipeline Challenges on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 11 Sep 2023 05:49:37 +0000</lastBuildDate><atom:link href="https://finan.club/tags/pipeline-challenges/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>GILD</title>
      <link>https://finan.club/us/gild/</link>
      <pubDate>Mon, 11 Sep 2023 05:49:37 +0000</pubDate>
      
      <guid>https://finan.club/us/gild/</guid>
      <description>score:60
Chances: Gilead&amp;rsquo;s Phase 2 EVOKE-02 Study of Trodelvy in Combination with KEYTRUDA demonstrates promising clinical activity in first-line metastatic non-small cell lung cancer, indicating potential growth opportunities. Gilead Sciences has a high institutional ownership of 86%, suggesting confidence from major investors. The FDA approval for Veklury to treat COVID-19 in people with hepatic impairment is a positive development for Gilead&amp;rsquo;s product portfolio.</description>
    </item>
    
  </channel>
</rss>
